<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">55415</article-id><article-id pub-id-type="doi">10.7554/eLife.55415</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Host Sirtuin 2 as an immunotherapeutic target against tuberculosis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-81412"><name><surname>Bhaskar</surname><given-names>Ashima</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7367-874X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-173911"><name><surname>Kumar</surname><given-names>Santosh</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-173912"><name><surname>Khan</surname><given-names>Mehak Zahoor</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-173913"><name><surname>Singh</surname><given-names>Amit</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-187882"><name><surname>Dwivedi</surname><given-names>Ved Prakash</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4321-2567</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-86539"><name><surname>Nandicoori</surname><given-names>Vinay Kumar</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5682-4178</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Signal Transduction Laboratory-1</institution>, <institution>National Institute of Immunology</institution>, <addr-line><named-content content-type="city">New Delhi</named-content></addr-line>, <country>India</country></aff><aff id="aff2"><institution content-type="dept">Immunobiology</institution>, <institution>International Centre for Genetic Engineering and Biotechnology</institution>, <addr-line><named-content content-type="city">New Delhi</named-content></addr-line>, <country>India</country></aff><aff id="aff3"><institution content-type="dept">Microbiology and Cell Biology</institution>, <institution>Indian Institute of Science</institution>, <addr-line><named-content content-type="city">Bangalore</named-content></addr-line>, <country>India</country></aff><aff id="aff4"><institution content-type="dept">Signal Transduction Laboratory</institution>, <institution>National Institute of Immunology</institution>, <addr-line><named-content content-type="city">New Delhi</named-content></addr-line>, <country>India</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-18245"><name><surname>Stallings</surname><given-names>Christina L</given-names></name><role>Reviewing editor</role><aff><institution>Washington University School of Medicine</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>ashimabhaskar@gmail.com</email> (AB);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>22</day><month>07</month><year>2020</year></pub-date><volume>9</volume><elocation-id>e55415</elocation-id><history><date date-type="received"><day>23</day><month>01</month><year>2020</year></date><date date-type="accepted"><day>20</day><month>07</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Bhaskar et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Bhaskar et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-55415-v1.pdf"/><abstract><p><italic>Mycobacterium tuberculosis</italic> (<italic>Mtb</italic>) employs plethora of mechanisms to hijack the host defence machinery for its successful survival, proliferation and persistence. Here we show that <italic>Mtb</italic> upregulates one of the key epigenetic modulators, NAD+ dependent histone deacetylase Sirtuin 2 (SIRT2), which upon infection translocate to the nucleus and deacetylates histone H3K18, thus modulating the host transcriptome leading to enhanced macrophage activation. Furthermore, in <italic>Mtb</italic> specific T cells, SIRT2 deacetylates NFκB-p65 at K310 to modulate T helper cell differentiation. Pharmacological inhibition of SIRT2 restricts the intracellular growth of both drug-sensitive and resistant strains of <italic>Mtb</italic> and enhances the efficacy of front line anti-TB drug Isoniazid in the murine model of infection. SIRT2 inhibitor-treated mice display reduced bacillary load, decreased disease pathology and increased <italic>Mtb</italic> specific protective immune responses. Overall, this study provides a link between <italic>Mtb</italic> infection, epigenetics and host immune response, which can be exploited to achieve therapeutic benefits.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001409</institution-id><institution>Department of Science and Technology, Ministry of Science and Technology</institution></institution-wrap></funding-source><award-id>NII/F-56/827/IFAD</award-id><principal-award-recipient><name><surname>Bhaskar</surname><given-names>Ashima</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: Animal experiments were carried out in accordance with the guidelines approved by the Animal Ethics Committee of National Institute of Immunology (NII, Approval ID: IAEC#409/16 &amp; IAEC#462/18), New Delhi, India, International Centre for Genetic Engineering and Biotechnology (ICGEB, Approval ID: ICGEB/AH/2015/01/IMM-45), New Delhi, India and the Department of Biotechnology (DBT) Government of India. Mice were ethically sacrificed according to institutional and DBT regulations.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript. Source data files have been provided for all the Figures.</p></sec><supplementary-material><ext-link xlink:href="elife-55415-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>